The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.
Revolutionizing Cardiac Regeneration.
Positive pre-IND meeting with FDA helps position CellProthera for a U.S. and international Phase III trial for...
The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and...
MULHOUSE, France, and SUNNYVALE, California USA - July 8, 2024 CellProthera, a private company specializing in cell-based therapies...
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.
Researchers harvest stem cells from patients who have recently had a heart attack and use them to trigger regeneration of their cardiac muscle.
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
New clinical trial data demonstrates the potential for a stem cell treatment as a cardiac regenerative therapy.